Stem Cell Therapy Shows Promise for In Utero Spina Bifida Treatment

A groundbreaking stem cell therapy is offering new hope for infants diagnosed with spina bifida, a serious birth defect affecting the spinal cord. A small clinical trial has demonstrated the safety of applying placenta-derived stem cells directly to the exposed spinal cords of fetuses during in utero surgery, with early indications of potential benefits.

Understanding Spina Bifida

Spina bifida, also known as myelomeningocele, is a neural tube defect that occurs when the spinal cord doesn’t close completely during gestation. Affecting fewer than 1 in 1,000 births globally, the condition is more prevalent in low-income countries. The most severe form can lead to paralysis, issues with bladder and bowel control, and potential brain damage due to excess fluid accumulation [1].

The CuRE Trial: A First-of-Its-Kind Approach

Led by Dr. Diana Farmer at the University of California, Davis, the Cellular Therapy for In Utero Repair of Myelomeningocele (CuRE) trial assessed the feasibility and safety of using stem cells derived from donated placentas to treat spina bifida before birth [2]. Six pregnant women underwent surgery at 24–25 weeks of gestation. During the procedure, surgeons exposed the fetal spine and applied a patch containing the stem cells directly to the affected area before closing the back to allow for tissue regeneration.

Key Findings and Safety Profile

The trial results, published in The Lancet, indicate that the stem cell therapy is safe. No complications were observed during or after the surgeries, and newborns delivered around 34 weeks of gestation showed no signs of infection, cerebrospinal fluid leakage, or tumor growth [2]. A significant concern regarding the use of stem cells – the potential for cancerous growth – was not observed in this initial trial.

Reversing Hindbrain Herniation

Notably, all newborns in the trial showed signs of reversal of hindbrain herniation, a complication of spina bifida where the back of the brain descends into the neck, potentially blocking cerebrospinal fluid circulation [1].

Current Treatment Landscape and Potential Impact

Currently, fetal surgery is used to close the spinal cord defect in utero. However, nearly 60% of children still experience difficulty walking or moving independently after the procedure. This is because the surgery doesn’t reverse the damage to neurons caused by exposure to amniotic fluid [2]. The addition of stem cells aims to protect the developing spinal cord and potentially improve motor function.

Looking Ahead

While these initial results are promising, experts caution that further research is needed. Clare Whitehead, a fetal-medicine specialist at the Royal Women’s Hospital in Melbourne, Australia, emphasizes the need for caution and larger studies to confirm the long-term benefits of this therapy [1]. Dr. Farmer envisions a future where this therapy could become the standard of care for spina bifida, significantly improving the quality of life for affected children [4].

Key Takeaways

• In utero stem cell therapy for spina bifida has demonstrated a promising safety profile in a small clinical trial.
• The therapy involves applying placenta-derived stem cells directly to the fetal spinal cord during surgery.
• Early indications suggest potential benefits, including reversal of hindbrain herniation.
• Larger studies are needed to confirm long-term efficacy and establish this as a standard treatment.